• Skip to main content

Hearing Loss Treatment Report

www.HearingLossTreatmentReport.com

ASOs

Antisense Oligonucleotides for the Treatment of Inner Ear Dysfunction

April 10, 2019

https://link.springer.com/article/10.1007%2Fs13311-019-00729-0

https://www.ncbi.nlm.nih.gov/pubmed/30972560?dopt=Abstract

Related Articles

Antisense Oligonucleotides for the Treatment of Inner Ear Dysfunction.

Neurotherapeutics. 2019 Apr 10;:

Authors: Hastings ML, Jones TA

Abstract

Antisense oligonucleotides (ASOs) have shown potential as therapeutic molecules for the treatment of inner ear dysfunction. The peripheral sensory organs responsible for both hearing and equilibrium are housed within the inner ear. Hearing loss and vestibular balance problems affect a large portion of the population and limited treatment options exist. Targeting ASOs to the inner ear as a therapeutic strategy has unique pharmacokinetic and drug delivery opportunities and challenges. Here, we review ASO technology, delivery, disease targets, and other key considerations for development of this therapeutic approach.

PMID: 30972560 [PubMed – as supplied by publisher]

Powered by Urgent Research

Copyright © 2025 Urgent Research